NASDAQ:EXEL
Exelixis Stock News
$22.15
+0.250 (+1.14%)
At Close: May 07, 2024
Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to $32
03:44pm, Monday, 01'st Jun 2020Biotech ETFs Are Soaring. These Four Are Still Worth Considering.
12:00pm, Monday, 01'st Jun 2020
Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even thoug
Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 49% Undervaluation?
10:58am, Thursday, 28'th May 2020
Today we will run through one way of estimating the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the...
3 Charts That Suggest Biotech Stocks Are Headed Higher
05:30pm, Wednesday, 20'th May 2020
Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.
Patent Filings Roundup: The Return of the Founder, Retailers Target Wireless LLC, European NPE Revives 2G/3G Patent Wars
04:15pm, Wednesday, 20'th May 2020
There were only 16 new patent filings at the Patent Trial and Appeal Board (PTAB)—all inter partes reviews (IPRs)—this week, with a whopping 70 new district court complaints filed.
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabo
SunTrust Robinson Humphrey Maintains Buy on Exelixis, Raises Price Target to $40
03:05pm, Thursday, 14'th May 2020Exelixis Reports Results From COSMIC-021 Trial Of Cabozantinib In Combo With Atezolizumab In Multiple Advanced Solid Tumor Types
09:08pm, Wednesday, 13'th May 2020Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
09:00pm, Wednesday, 13'th May 2020
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or meta
Better Buy: bluebird bio vs. Exelixis
01:54pm, Wednesday, 13'th May 2020
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains
Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
12:00am, Wednesday, 13'th May 2020
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECEN
6 Stock Charts To Watch: AMRS, CYTK, DRNA, LX, MRNA, VAPO
12:00am, Tuesday, 12'th May 2020
Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Amyris Inc, BioCryst Pharmaceuticals Inc, Cytokinetics Inc. Read Harry Boxer's latest article on Investing.com
